Ketamine is NOT a guideline-recommended therapy for persistent ventricular tachycardia refractory to standard antiarrhythmics
Ketamine should not be used as an antiarrhythmic agent for terminating refractory VT—instead, proceed immediately to synchronized cardioversion, consider transvenous pacing, or pursue catheter ablation.
The Standard Treatment Algorithm for Refractory VT
When VT persists despite amiodarone, lidocaine, and esmolol, established guidelines provide clear next steps 1:
Immediate Actions:
- Direct-current cardioversion with appropriate sedation is the Class I recommendation at any point when VT is hemodynamically unstable or refractory to medications 1
- Transvenous catheter pace termination (Class IIa) is specifically indicated for sustained monomorphic VT that is refractory to cardioversion or frequently recurrent despite antiarrhythmic medication 1
Additional Pharmacologic Options:
- Intravenous procainamide (Class IIa) if not already tried—more appropriate than amiodarone for early termination of stable monomorphic VT 1
- Sotalol (Class IIb) may be considered, though recent evidence suggests similar efficacy to procainamide 2, 3
Definitive Management:
- Urgent catheter ablation for VT refractory to cardioversion or recurrent despite medications 1
- Urgent coronary angiography with revascularization if ischemia suspected or cannot be excluded, particularly for polymorphic VT 1
Why Ketamine Is Not the Answer
The evidence base is critically insufficient:
Only one case report exists 4 describing ketamine terminating persistent VT in a patient with ischemic cardiomyopathy. This 2024 single-case publication provides no mechanistic data, no dosing guidance, and no safety profile for this indication. A case report represents the lowest tier of medical evidence and cannot support clinical recommendations for life-threatening arrhythmias.
No guidelines mention ketamine for VT management. The comprehensive ACC/AHA/ESC guidelines 1, 2010 and 2025 AHA ACLS guidelines 5, 2, and the 2026 HRS antiarrhythmic drug statement 3 make zero reference to ketamine as an antiarrhythmic option.
Ketamine's role is sedation, not rhythm control. When guidelines recommend "appropriate sedation" before cardioversion 1, 2, ketamine may serve this purpose—but the therapeutic intervention is the cardioversion itself, not the sedative agent.
Critical Pitfalls to Avoid
Do not delay definitive therapy by attempting unproven pharmacologic interventions. Each minute in refractory VT increases mortality risk and myocardial damage.
Do not confuse sedation with treatment. If ketamine appeared to terminate VT in isolated cases, this likely represents either:
- Coincidental spontaneous termination
- Hemodynamic effects altering the arrhythmia substrate
- The sedation facilitating more effective cardioversion
Do not extrapolate from seizure data 6. Ketamine's NMDA antagonism may have anticonvulsant properties, but seizures and cardiac arrhythmias have entirely different pathophysiology.
The Evidence-Based Approach
For persistent VT despite amiodarone, lidocaine, and esmolol:
- Cardiovert immediately if hemodynamically unstable 1, 2
- Consider procainamide if stable and not previously administered 1
- Pursue transvenous pacing for pace-terminable VT 1
- Arrange urgent catheter ablation for medication-refractory cases 1
- Evaluate for ischemia and revascularize if indicated 1
The 2026 HRS statement 3 addresses combination antiarrhythmic therapy for refractory ventricular arrhythmias, recommending mexiletine as adjunct to amiodarone, or quinidine with mexiletine—but notably, ketamine receives no mention even in this discussion of salvage therapies.
The single case report 4 is insufficient to justify ketamine use when proven, guideline-supported interventions remain available. In emergency medicine, we prioritize therapies with established efficacy, known safety profiles, and guideline support—none of which exist for ketamine in this indication.